top of page

This page is intended for educational purposes, using scientific exchange around the OMIDRIA experience.

Surgical Cases
Preoperative Poor Dilation

Stability of pupil size throughout the entire case

IFIS-Risk Patient

Patient currently using an ɑ-blocker

Hyperopia + Tamsulosin

Patient with +2D hyperopia and tamsulosin history

Patients At-Risk for IFIS

ɑ-blocker history: a side by side OMIDRIA/No OMIDRIA

Intraoperative Miosis

Intraoperative miosis without ɑ-blocker history

Peer2Peer Perspectives
Witness Dramatic Change

See why Drs. Wiley and Hura started using OMIDRIA

Witness-Dramatic-Change-video-thumbnail.original.jpg
Now Playing
One Vial, Lasting Effects

OMIDRIA’s intra- and postoperative experience

Witness-Dramatic-Change-video-thumbnail.original.jpg
Now Playing
The Proof Is in the Post-Op

Learn why Drs. Wiley and Hura recommend OMIDRIA

Witness-Dramatic-Change-video-thumbnail.original.jpg
Now Playing
The Ketorolac Effect

Learn how OMIDRIA suppresses COX-1 and COX-2

Witness-Dramatic-Change-video-thumbnail.original.jpg
Now Playing
Proven to Maintain Dilation

Hear Dr. Walter describe OMIDRIA’s effect on miosis

Witness-Dramatic-Change-video-thumbnail.original.jpg
Now Playing
A Case of Premium Outcomes

See how OMIDRIA supports patients’ desired outcomes

Witness-Dramatic-Change-video-thumbnail.original.jpg
Now Playing
I Wasn’t an Early Adopter

Hear about Dr. Walter’s journey to using OMIDRIA

Witness-Dramatic-Change-video-thumbnail.original.jpg
Now Playing
A Prospective Study

Hear Dr. Silverstein share OMIDRIA Study Results

Witness-Dramatic-Change-video-thumbnail.original.jpg
Now Playing
Why I Choose OMIDRIA

See why Dr. Walter recommends OMIDRIA

Witness-Dramatic-Change-video-thumbnail.original.jpg
Now Playing
OMIDRIA Study Results

Drs. Visco and Walter discuss OMIDRIA study and results

Witness-Dramatic-Change-video-thumbnail.original.jpg
Now Playing
The Challenges of Miosis

Dr. Silverstein on the impact of pupillary miosis

Witness-Dramatic-Change-video-thumbnail.original.jpg
Now Playing
Walter: OMIDRIA Benefits

Hear how OMIDRIA can benefit you and your patients

Witness-Dramatic-Change-video-thumbnail.original.jpg
Now Playing
Visco: OMIDRIA Benefits

Hear how OMIDRIA can benefit your practice

Witness-Dramatic-Change-video-thumbnail.original.jpg
Now Playing

EXPLORE SURGEON PERSPECTIVES

Indications and Usage

OMIDRIA® is added to ophthalmic irrigating solution used during cataract surgery or intraocular lens replacement and is indicated for maintaining pupil size by preventing intraoperative miosis and reducing postoperative ocular pain.

Important Safety Information

OMIDRIA must be added to irrigating solution prior to intraocular use.

OMIDRIA is contraindicated in patients with a known hypersensitivity to any of its ingredients.
Systemic exposure to phenylephrine may cause elevations in blood pressure.
Use OMIDRIA with caution in individuals who have previously exhibited sensitivities to acetylsalicylic acid, phenylacetic acid derivatives, and other nonsteroidal anti-inflammatory drugs (NSAIDs), or have a past medical history of asthma.
The most commonly reported adverse reactions at ≥ 2% are eye irritation, posterior capsule opacification, increased intraocular pressure, and anterior chamber inflammation.
Please see the Full Prescribing Information for OMIDRIA.
You are encouraged to report Suspected Adverse Reactions to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Indications and Usage

OMIDRIA® is added to ophthalmic irrigating solution used during cataract surgery or intraocular lens replacement and is indicated for maintaining pupil size by preventing intraoperative miosis and reducing postoperative ocular pain.

Important Safety Information

OMIDRIA must be added to irrigating solution prior to intraocular use.

OMIDRIA is contraindicated in patients with a known hypersensitivity to any of its ingredients.
Systemic exposure to phenylephrine may cause elevations in blood pressure.
Use OMIDRIA with caution in individuals who have previously exhibited sensitivities to acetylsalicylic acid, phenylacetic acid derivatives, and other nonsteroidal anti-inflammatory drugs (NSAIDs), or have a past medical history of asthma.
The most commonly reported adverse reactions at ≥ 2% are eye irritation, posterior capsule opacification, increased intraocular pressure, and anterior chamber inflammation.
Please see the Full Prescribing Information for OMIDRIA.
You are encouraged to report Suspected Adverse Reactions to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

bottom of page